REPO4EU

How can we build a patient-centered approach to #DrugRepurposing? How can we find the balance between providing fair return on investments for companies backing repurposed drugs while ensuring patients can afford these treatments? How can regulators and researchers collaborate to reshape the #FutureOfMedicine? 💊 These were some of the questions tackled during the hybrid policy kick-off event that took place in Brussels (and online) on 15 January 2025, organised by REPO4EU in close collaboration with REMEDi4ALL and the support of European Health and Digital Executive Agency (HaDEA). If you missed it, read the recap article with the top highlights of the four panel discussions ➡️ https://lnkd.in/gB3279Kw This event marks a huge step forward into our continuous commitment towards driving EU-wide and global cooperation for drug repurposing. It wouldn't have been possible without the #REPO4EU community involved, including Project Coordinator Harald H.H.W. Schmidt, as well as the members of the consortium and invited panellists who shared their expert insights during the discussions. We've received many emails and messages since the event, and there's one common thread throughout: how professionally moderated it was. The credit goes to Artur Olesch, our wonderful moderator! We look forward to working with him again in the future. The full agenda and list of panellists is also available on our website: https://lnkd.in/eFx-XYCA David Cavalla, Monica Ensini, Marcos Mengual Hinojosa, Anneliene Jonker, Ellen Koekoeckx, Joachim Maurice Mielert, Bernd Rosenbichler, Matthew Fedowitz, Aaron S. Kesselheim, M.D., J.D., M.P.H., Yoana Nuevo-Ordóñez, PhD, Marjon Pasmooij, Anja Schiel, Saco de Visser, Hugo Filipe, Teun Grooters, Hermann Mucke, François Houÿez, Sabine Grimm, Sibylle R., Sibren van den Berg.

Sifting through the vast amount of scientific literature can be overwhelming, especially in fast-evolving fields like #DrugRepurposing 💊 ♻️ To tackle this, experts from the REPO4EU Consortium have joined forces to develop DrugRepoChatter, an AI-powered tool that helps researchers navigate through the relevant literature for mechanism-based drug repurposing in a faster and more efficient way. Bioinformatician Fernando M. Delgado-Chaves, one of the REPO4EU partners involved in the development of DrugRepoChatter, explains how the tool works and its capabilities ➡️ https://lnkd.in/efWmCg-K REPO4EU Consortium partners involved: University of Hamburg / CoSyBio, Technical University of Munich / DaiSyBio, GeneSurge, STALICLA, University of Vienna, Brigham and Women's Hospital, Maastricht University and H.M. Pharma Consultancy. 🇪🇺 #EUfunded by European Health and Digital Executive Agency (HaDEA)

🎙️ Repurposing vs. Designing Novel Drugs: Where Do We Go From Here? In our latest podcast episode, we dive into a crucial debate in drug discovery: the advantages and challenges of AI-driven drug design versus the untapped potential of repurposing existing compounds. 💡 Key insights: AI can help design novel molecules targeting specific diseases, creating strong patents but facing the uncertainties of starting from scratch in drug discovery. Repurposing drugs offers a faster route with extensive safety data from millions of patients, making it a compelling option. COVID-19 showcased the power of repurposing as the world sought existing drugs to combat the pandemic. Technology, including platforms like Delta4's Hyper-C, has revolutionized the identification of "hidden effects" in drugs, unlocking new opportunities to address untreated diseases. 🎯 Striking a balance is vital. Big pharma should continue innovating new therapies, but leveraging AI and repurposing technologies allows us to treat diseases more efficiently, maximizing what’s already available. 🔗 Tune in to the full discussion to explore how this dual approach is shaping the future of healthcare! https://lnkd.in/eTBqWmKc What’s your take? Should the industry embrace repurposing more actively? Let us know in the comments! #DrugDiscovery #AI #Repurposing #PharmaInnovation #Delta4

"Science is fun and being a scientist is a fun job!" On this year's International Day for Women and Girls in Science, listen to 2023 medicine laureate Katalin Karikó speak about being a scientist. What is your favourite thing about being a scientist? #womeninscience

#ScienceFridays 🔬 Research paper of the week ➡ ‘Transforming literature screening: The emerging role of large language models in systematic reviews’ 🔎 Abstract: Large language models (#LLMs) can effectively be used to pre-filter scientific records for systematic reviews, leading to a substantial reduction in manual workload. In this study, led by REPO4EU consortium members, researchers conclude that LLMs can help to reduce reviewers’ workload between 33% and 93% during title and abstract screening. ✍️ Authors: Fernando M. Delgado-Chaves, Matthew Jennings, Antonio J Marques Atalaia, Dr. Justus Wolff, Rita Horvath, Zeinab Mamdouh, Jan Baumbach and Linda Baumbach, Ph.D. 🏫 Affiliations: CoSyBio at University of Hamburg, Columbia Systems Biology at Columbia University, Sorbonne Université, University of Cambridge, Maastricht University, Zagazig University, Department of Mathematics and Computer Science (IMADA), University of Southern Denmark (SDU), University Medical Center Hamburg-Eppendorf, Center for Bioinformatics Hamburg and Syte 📄 Published on: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Find the link to the article on our #DrugRepurposing Research Collection, curated via ScienceOpen 🔗 https://lnkd.in/eMgzWpNd #FutureOfMedicine #OpenScience #Bioinformatics #Biomedicine

🚨 Out now in the Journal of Law, Medicine, & Ethics: Analysis co-led by Mirre Scholte and Liam Bendicksen with REPO4EU consortium collaborators details the pathways available to bring repurposed drugs to market in the US, EU, and UK. They discuss the challenges academic & non-profit institutions may face in commercializing repurposed drugs and call for greater governmental support for drug repurposers and #DrugRepurposing research. Read here: https://lnkd.in/es3--Txk Mirre Scholte, Bianca Pauly, Manuela Joore, Aaron S. Kesselheim, M.D., J.D., M.P.H. Teebah Abu-Zahra طيبة أبوزهرة

Congratulations are in order for Johannes Kersting, one of REPO4EU's PhD researchers! 🎉 Johannes, who is doing his doctorate at Technical University of Munich's DaiSyBio, has won the ASAPbio Poster Prize for his poster presentation titled 'A Nextflow Pipeline for Network-Based Disease Module Identification and Validation'. Following the competition's ethos to foster the transparent and early sharing of data, the organisers praised Johannes' work for his "impressive commitment to research openness", highlighting the fact that his poster was the most consistently highly scored by the judges. Our colleagues from ScienceOpen have also celebrated Johannes' achievement with a dedicated article on their blog! Find out how he reacted to the news after receiving the award ➡️ https://lnkd.in/dv7aYSDQ

Systems medicine is a great example to the contrary, a perfect example of interdisciplinary research. Lots of disciplines joining forces to achieve for the first time fast and precision patient benefit. No discipline on its own could achieve that. REPO4EU

🎙️ Repurposing Drugs, Expanding Indications: The Power of Network Biology 🌐💊 At Delta4, we leverage a computational network biology approach to bridge the gap between drugs and diseases. By ingesting vast amounts of public domain data, we create a knowledge graph—a network representation of the world’s collective biomedical knowledge. Here’s how it works: 1️⃣ We build disease-specific molecular models to represent drugs and diseases as networks. 2️⃣ These networks are overlaid to identify optimal matches between existing compounds and unmet medical needs. 3️⃣ Every potential match undergoes rigorous evaluation—both algorithmic and manual—to determine if a compound could address a disease effectively. Whether it’s drug repurposing, indication expansion, or API rediscovery, our approach uncovers new possibilities for existing compounds. With a catalog of over 8,000 diseases, we believe many could be addressed with drugs already on the market, waiting to be rediscovered. 💡 The future of drug discovery doesn’t always start from scratch—it begins with a smarter use of what we already have. What are your thoughts on Network Biology and Drug Rediscovery? Share below! 👇 #DrugDiscovery #NetworkBiology #Repurposing #PharmaInnovation #Healthcare

Meet our #DrugRepurposing Community member 👉 RePo-SUDOE, the EU-funded initiative aiming to increase the competitiveness of drug repurposing efforts across the south of Europe by boosting the biopharmaceutical industry in Spain, Portugal and France. The project is coordinated by Hugo Filipe from Politécnico da Guarda, working alongside researchers from 6 other partner institutions: Universidade da Coruña, Universidad de Santiago de Compostela, MD.USE Innovations, Sociedade Portuguesa de Saúde Pública - Portuguese Society of Public Health, CNRS and Cluster Saúde de Galicia, CSG. RePo-SUDOE will contribute towards #REPO4EU's mission to build a global, multidisciplinary infrastructure for validated precision drug repurposing – one that is open to all to access information and to foster capacity building, matchmaking and cooperation. Thanks for joining us in our journey to reshape the present and future of #NetworkMedicine! ⚕️ Check their profile on our website ➡ https://lnkd.in/dVc_aQ4g Learn more about our ambition to build a global drug repurposing community to facilitate cooperation and knowledge exchange 💊 https://lnkd.in/dt6fwHuu